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Abstract
Background: Mutations in GATA6 are the most frequent cause of pancreatic agenesis. Most cases present with
neonatal diabetes mellitus.
Case presentation: The case was a female born after an uncomplicated pregnancy and delivery in a non-
consanguineous family (3.59 kg, 70th percentile). Severe cardiac malformations were diagnosed at two and a half
months old. No hyperglycaemic episodes were recorded in the neonatal period. Diabetes was diagnosed at 21
years due to the detection of incidental glycosuria. She had a low but detectable C-peptide level at diagnosis. Anti-
GAD and Islet-cell antibodies were negative and she failed oral hypoglycaemic therapy and was started on insulin.
Abdominal MRI revealed the absence of most of the neck, body, and tail of pancreas with normal pancreas elastase
levels. Criteria for type 1 or type 2 diabetes were not fulfilled, therefore a next generation sequencing (NGS) panel
was performed. A novel heterozygous pathogenic GATA6 mutation (p.Tyr235Ter) was identified. The GATA6 variant
was not detected in her parents, implying that the mutation had arisen de novo in the proband.
Conclusion: Rarely GATA6 mutations can cause adult onset diabetes. This report highlights the importance of
screening the GATA6 gene in patients with adult-onset diabetes, congenital cardiac defects and pancreatic agenesis
with no first-degree family history of diabetes. It also emphasizes the importance of genetic counselling in these
patients as future offspring will be at risk of inheriting the variant and developing GATA6 anomalies.
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Background
The formation of beta-cells during embryonic develop-
ment is regulated by several transcription factors (TFs)
that activate specific genes. Many of these TFs are also
important in pancreas function during adult life [1]. The
GATA family represents a group of conserved zinc
finger TFs involved in development and differentiation
of eukaryotic organisms. Two subgroups have been de-
scribed in vertebrates, including the hematopoietic
GATA1/2/3 and cardiac groups GATA 4/5/6 [2]. This
last group is expressed in tissues of endodermal and
mesodermal origin including gut, lung, heart and pan-
creas [3]. Mutations in GATA6 are the most frequent
cause of pancreatic agenesis [4, 5]. It is also associated
with neonatal diabetes mellitus (NDM), congenital car-
diac malformations and other extrapancreatic features
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: bsanchezle@gmail.com
1Department of Diabetes & Endocrinology, Mater Misericordiae University
Hospital, Dublin 7, Ireland
Full list of author information is available at the end of the article
Sanchez-Lechuga et al. BMC Medical Genetics           (2020) 21:70 
https://doi.org/10.1186/s12881-020-01012-2
such as biliary tract defects, gut abnormalities [4, 6] and
significant neurocognitive deficit [5, 7]. The most com-
mon pancreatic feature is diabetes occuring in 98% of
cases. The vast majority of cases present with NDM, but
a small proportion develop adolescent or adult onset
diabetes [7].. This report describes a 21 year old female
diagnosed with adult-onset diabetes associated with con-
genital heart defects and pancreatic agenesis associated
with a de novo heterozygous mutation in the GATA6
gene.
Case presentation
She was born at 40 weeks gestation after an uncompli-
cated pregnancy and delivery in a non-consanguineous
family. Her birth weight was 3.59 kg (70th percentile).
She was diagnosed with a severe cardiac malformation
(subaortic ventricular septal defect, small atrial septal de-
fect and moderate patent ductus arteriosus) at two and a
half months old. At 5 months old, coartation repair,
PDA ligation and pulmonary artery banding were per-
formed. Some months later she had the VSD repaired
and pulmonary artery deep banding. She had mild
residual coarctation, bicuspid aortic valve with mild aor-
tic stenosis and mild aortic incompetence. She had nor-
mal growth with adult height of 165 cm. She also had
scoliosis and hypertension (on losartan 100 mg). She
completed secondary school and works as a health care
assistant. No hyperglycaemic episodes were recorded in
the neonatal period. At 21 years old, incidental glyco-
suria was detected and diagnosis of diabetes was con-
firmed. Baseline fasting bloods showed glucose 9 mmol/
l, Insulin 19.7 mUI/l (2–25) and C-peptide 2.8 μgr/l
(1.1–4.1). HbA1c was 61 mmol/mol, and anti-GAD and
Islet cell antibodies were negative. Pituitary and thyroid
function were normal. On examination, BP was 102/72
mmHg, HR 74 bpm and BMI was 24.3 kg/m2. She has
no features of insulin resistance: no striae, acanthosis
nigricans or skin tags. She had a 2/6 aortic ejection sys-
tolic murmur with a 2/4 early diastolic murmur. Signifi-
cant scoliosis was noted. She was started on metformin,
but this was discontinued due to gastrointestinal side ef-
fects, and gliclazide MR 30mg once daily was started.
There was a positive family history of diabetes shown in
Fig. 1. There was no family history of cardiac defects or
Fig. 1 Family pedigree. An arrow points to the index case. Squares represent male family members, and circles represent female family members.
Filled black symbols represent people with diabetes. Genotype is shown underneath each symbol. N/N denotes no mutation identified
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pancreatic agenesis. Her mother reported a still birth at
7 months before the index case was born (unknown
cause of death).
She was referred with atypical diabetes to the maturity
onset diabetes of the young (MODY) clinic in 2017 with
a HbA1c of 59 mmol/l on gliclazide which was increased
to 60mg daily. An oral glucose test was performed (14
months after diagnosis) off treatment for 2 days. Fasting
glucose was 10.3 mmol/l and her 2-h post load glucose
was 18.4 mmol/l; fasting C-peptide was 484 pmol/l and
2 h post load was 512 pmol/l. Subsequently, gliclazide
MR was titrated to 120 mg daily. Three months later
blood glucose level was 32mmol/l (HbA1c 95 mmol/
mol) and gliclazide was discontinued. Multiple dose in-
jection therapy was started. Her current HbA1c is 45
mmol/l on 25 units of insulin daily. Incidentally, during
investigations for other disorders, an abdominal mag-
netic resonance imaging revealed the absence of most of
the neck, body and tail of pancreas (Fig. 2). Pancreas
elastase was > 500 μg/g (normal > 200 μg/g). She had no
evidence of background retinopathy and her microalbu-
minuria to creatinine ratio was normal.
Patient did not meet criteria for either type 1 or type 2
diabetes and was categorized as “Other diabetes”. A muta-
tion in hepatocyte nuclear factor 1B was suspected initially
given her diabetes profile and pancreatic agenesis. A renal
and pelvic ultrasound scan was performed and no abnor-
mality was detected. Targeted NGS analysis of 34 known
monogenic diabetes genes identified a novel heterozygous
pathogenic GATA6 nonsense variant, (p.Tyr235Ter)
(NM_005257.5:c.705C >G) in exon 2. This variant is clas-
sified as pathogenic class 5 according to the AMCG guide-
lines [8]. The variant generates a premature termination
codon in exon 2 and the mRNA transcripts are predicted
to undergo nonsense mediated decay, resulting in haploin-
sufficiency for GATA6 (Fig. 3).
The GATA6 variant was not detected in peripheral
blood samples from her non diabetic parents (mother
HbA1c 28mmol/mol, FPG 3.9 mmol/l and father HbA1c
37mmol/mol, FPG 5.5 mmol/l) and maternal grand-
mother (Fig. 1), implying that the mutation had arisen
de novo in the proband. Low level somatic mosaicism in
both parents was excluded to a level of ≥5%. The possi-
bility of germline mosaicism could not be excluded.
Discussion and conclusion
This report describes a 21 year old female diagnosed
with adult-onset diabetes associated with atrial septal de-
fect, subaortic ventricular septal defect, patent ductus
arteriosus and pancreatic agenesis and a novel de novo
heterozygous mutation (p.Tyr235Ter) in the GATA6 gene.
Pancreatic agenesis is a rare disorder resulting in
NDM associated with exocrine pancreatic insufficiency
[9]. The commonest cause of pancreatic agenesis or hypo-
plasia is heterozygous inactivating mutations in GATA6
[5, 7, 10].. The prevalence of GATA6 mutations is unclear
but a few studies have shown that mutations account for
at least 3% of NDM and 54% of patients with pancreatic
agenesis [5]. The most common phenotypes are congeni-
tal cardiac defects, particularly outflow tract malforma-
tions such as atrial and ventricular septal defects or
tetralogy of Fallot [4]. GATA6 mutations can also lead to
several other phenotypes: congenital biliary tract anomal-
ies (17%), gut developmental disorders (21%), neurocogni-
tive (38%) and additional endocrine abnormalities (24%,
hypothyroidism/hypopituitarism) [4, 5, 7].
Pancreatic agenesis or hypoplasia can cause permanent
NDM and has been associated with mutations in TFs
important for β cell and pancreatic development.,
GATA6 is the most common of these mutations [11]..
The severity of diabetes varies among family members,
ranging from NDM with only a remnant of pancreatic
tissue to adult-onset diabetes associated with dorsal
agenesis of the pancreas [12–14]. The mechanism
whereby GATA6 mutations result in associated clinical
phenotypes is still not completely understood.. The mu-
tation (p.Tyr235Ter) in the GATA6 protein occurs in
the transcriptional activation domain which is full of
pathogenic variants. There are multiple nonsense muta-
tions close by and even a missense mutation on the
same amino acid. A recent publication by Škorić-Milo-
savljević et al. [15], highlights the broad mutational and
clinical spectrum and lack of genotype-phenotype correl-
ation in patients with GATA6 mutations. Their study
showed that 58% of probands had de novo mutations
and these patients had more frequently anomalies of in-
tracardiac connections and the great arteries and they
were more likely to have hypothyroidism when
Fig. 2 Abdominal MRI axial and coronal image revealing the
absence of most of the neck, body and tail of pancreas
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compared to patients who had inherited a mutation.
Our patient did not have hypothyroidism. The pheno-
typic spectrum suggests the existence of modifier genes.
This is a syndromic disorder, and therefore by its nature
will have a variable clinical phenotype and penetrance
just as we see with other dominantly inherited syn-
dromic forms of diabetes such as HNF1B where there is
no genotype-phenotype correlation [16].
De Franco et al. [5] found that while investigating 171
patients with neonatal diabetes, four parents with heterozy-
gous GATA6 mutations (c.1136-2A >G, p.(Tyr323*),
p.(Thr346fs) p.(Gly469Glu), were diagnosed with adoles-
cent or adult-onset diabetes (12–46 years). A retrospective
study for pancreatic donors with diabetes showed a 16 years
old girl diagnosed with GATA6 mutation p.(Arg456Cys)
and adolescent-onset diabetes [14]. It remains unclear if
environmental factors or the different genetic background
of other genes can interact with GATA6 [13]. Reviewing
the literature, a de novo mutation in GATA6 p.(Arg456His)
was recently shown to be associated with young adult-onset
diabetes type 1 at age 22 in a patient with pancreatic hypo-
plasia [15]. The other two patients with adolescent or
adult-onset diabetes (c.1504_1505delAA) were detected
due to investigations for family members with neonatal dia-
betes [13]. The mutations do not represent a separate class.
Summarizing, it has been described a total of 3 adolescents
and 5 adults onset diabetes. Interestingly, our patient did
not show growth retardation or failure to thrive. In
addition, her faecal elastase levels were normal and she only
developed diabetes at age 21 years. This is consistent with a
previous report of phenotypic heterogeneity ranging from
pancreatic agenesis to adult onset diabetes with no evidence
of exocrine pancreatic insufficiency [5]. Her findings are
consistent with dorsal pancreatic agenesis as previously
Fig. 3 Sanger sequencing electropherogram of GATA6 exon 2 showing the heterozygous C > G single base substitution at nucleotide position
705 (c.705C > G) resulting the nonsense variant (p.Tyr235Ter) in the proband. The variant is absent in electropherograms from mother and father.
Sanger sequencing is able to detect low level somatic mosaicism to a level of approximately 5–10%
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described in patients with adolescent or adult onset dia-
betes with GATA6 mutations [12, 13]. Interestingly, she
failed sulphonylurea therapy and required insulin within 13
months of diagnosis. There is not an extensive description
in the literature of the diabetic treatment of GATA6 pa-
tients who develop adolescent or adult onset diabetes. In
fact there are only 8 cases described and 6 were treated
with insulin, one with metformin and one treatment un-
known [5, 13–15].
It should be emphasized that the use of targeted NGS
for clinical diagnostic testing will increase the number of
patients with a confirmed diagnosis of monogenic dia-
betes. NGS technology enables the potential for simul-
taneous analysis of all the known disease genes in a
single assay at a similar cost to analysing a few genes by
Sanger sequencing [17]. Despite the fact that the major-
ity of GATA6 mutations occur de novo, a small number
of dominantly inherited cases have been reported [12].
Yorifuji et al. [13] reported the case of a family with a
dominantly inherited mutation and neonatal complica-
tions resulting in death in 3 of 4 pregnancies. A genetic
diagnosis is important since it defines the diagnostic
subtype, determines the most appropriate treatment and
informs the sibling recurrence risk or risk of GATA6
associated anomalies in offspring.
In conclusion, this report describes a heterozygous
novel GATA6 mutation (p.Tyr235Ter) resulting in the
clinical picture of congenital heart defects, dorsal pan-
creas agenesis and adult-onset diabetes in a patient with
no first-degree family history of diabetes. It emphasizes
the importance of screening the GATA6 gene in young
patients with diabetes and congenital cardiac defects. It
also highlights the importance of genetic counselling in
these patients as future offspring will therefore be at risk
of inheriting the variant and possibly developing a much
more severe phenotype that could include pancreatic
agenesis and congenital heart defects.
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